Eli Lilly stock price target

What happened: Eli Lilly's stock has gained over 6% in the past month, with analysts predicting a further 13.6% upside. Leerink raised its price target to $1,232, maintaining an Outperform rating. Jim Cramer, on multiple occasions, has praised Eli Lilly's CEO and obesity drug pipeline, stating he can't sell the stock despite its run-up. Analysts predict the stock could reach $1,200 by 2026.

Market impact: Eli Lilly's bullish narrative is driven by its dominant GLP-1 franchise and expanding obesity drug pipeline. The company's strong performance and growth prospects have pushed its stock price higher, benefiting shareholders. The positive outlook on Eli Lilly may also positively impact the broader pharmaceutical sector.

What to watch next: Investors should monitor Eli Lilly's Q2 earnings release on July 28, which will provide insights into the company's recent performance. Additionally, they should keep an eye on regulatory decisions regarding Eli Lilly's obesity drug pipeline, particularly the Phase 3 results for retatrutide, expected in 2023.